Reasons to hope and reasons to keep perspective on a vaccine
By anchoring our hopes firmly to advancements in medical science, we will avoid reacting to well-meaning but potentially misguided enthusiasm or doubts.
MA in Engineering, École Central Paris; MSc in Chemical Engineering, University of Minnesota; MBA, Harvard Business School. President and Chief Executive Officer, Moderna Therapeutics, a biotechnology company that researches and develops protein therapies based on novel messenger RNA technology. Former: Executive Director, Global Manufacturing Strategy and Supply Chain, Eli Lilly, Indianapolis, Indiana; Managing Director, Eli Lilly, Belgium; Chief Executive Officer, bioMérieux, a world leader in the diagnostics industry. Supervisory Director, Qiagen; Executive Chairman of the Board, BG Medicine; Member, Board of Directors, Syros Pharmaceuticals. Named as an inventor on over 45 patent application filings in the field of messenger RNA technology. Recipient of honours and awards, including: best CEO for investor relations in France (2009); ranked the number one CEO in the biotech sector, 2011 Thomson Reuters EXTEL Study.